|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2016 ) Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.
Publisher's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.
View Report: http://www.reportsweb.com/global-hemophilia-b-market-2015-2019-industry-analysis .
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.
Publisher's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.
Key regions
- Americas
- APAC
- EMEA
Key vendors
- Baxter
- Grifols
- Novo Nordisk
- Pfizer
Inquire Before Buying at http://www.reportsweb.com/inquiry&RW0001232357/buying .
Other prominent vendors
- Alnylam
- Amarna
- Asklepios
- Biogen
- Catalyst Biosciences
- CSL Behring
- Dimension Therapeutics
- Dong-A Scio
- Emergent BioSolutions
Key market driver
- Prophylactic treatment
- For a full, detailed list, view our report
Key market challenge
- High cost of therapy
- For a full, detailed list, view our report
Key market trend
- New technological advancements
- For a full, detailed list, view our report
Buy Now at http://www.reportsweb.com/buy&RW0001232357/buy/2500 .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
